Inhibition of tumour growth in vivo by two NSCLC cell lines expressing wild-type EphA3, but not EphA3 mutants, shows that the EphA3 can act as a tumour suppressor in lung cancer [64]. This evidence concerns the gene EPHA3 and non-small cell lung carcinoma.